Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

NCT03446911 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage I

Interventions

RADIATION: SABR
COMBINATION_PRODUCT: SABR + pembrolizumab

Sponsor

Amsterdam UMC, location VUmc